Thermo Fisher Reports Strong Q4 and Full Year 2025 Results, Driven by Revenue and EPS Growth

summarizeSummary

Thermo Fisher Scientific announced strong fourth quarter and full year 2025 financial results, with notable growth in revenue and EPS, supported by strategic capital deployment and innovation.

check_boxKey Events

• Strong Fourth Quarter Performance

  Fourth quarter 2025 revenue grew 7% to $12.21 billion, with GAAP diluted EPS increasing 9% to $5.21 and adjusted EPS growing 8% to $6.57.

• Solid Full Year 2025 Results

  Full year 2025 revenue increased 4% to $44.56 billion, while GAAP diluted EPS grew 7% to $17.74 and adjusted EPS rose 5% to $22.87.

• Significant Capital Deployment

  The company deployed approximately $16.5 billion in 2025, including $13 billion for M&A, completing acquisitions like Solventum's Filtration and Separation business and Sanofi's Ridgefield site, and announcing the acquisition of Clario. Additionally, $3.6 billion was returned to shareholders through buybacks and dividends.

• Strategic Growth Initiatives

  Thermo Fisher advanced its growth strategy through new product launches, including the Thermo Scientific Orbitrap Astral Zoom mass spectrometer, and established strategic collaborations with OpenAI and the Chan Zuckerberg Institute for Advanced Biological Imaging.

auto_awesomeAnalysis

Thermo Fisher Scientific delivered robust financial results for both the fourth quarter and full year 2025, demonstrating consistent growth in revenue and earnings per share. The company's strategic execution, including significant capital deployment for M&A and shareholder returns, alongside innovative product launches and key collaborations, underpins its strong market position. These results reinforce the company's positive trajectory and operational efficiency, providing a solid foundation as it enters 2026.